A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence.
Drug use has been associated with craving, which may be described as a powerful and sometimes overwhelming urge to use the drug. Patients seeking treatment for methylamphetamine dependence must cope with drug cravings as they engage in psychosocial treatments. Changes in brain GABA(A) receptors during substance use and withdrawal provide a neurobiological basis for craving and associated anxiety. Flumazenil (a benzodiazepine antagonist) plus gabapentin (an antiepileptic) were compared with placebo in a randomized, double-blind study to assess the effects on craving during initial treatment for methylamphetamine dependence. Evaluation was conducted over a 30-day period. Craving and drug use were found to be highly correlated. Craving was reduced significantly in the flumazenil plus gabapentin group compared with placebo following the initial treatment period and throughout the 30 days. Decreased methylamphetamine use was also observed, as measured by urine drug screens and self-reports.
Urschel
Harold C
HC
Research Across America, CNS Research Group, Dallas, TX, USA. urschel@recovery-science.com
Hanselka
Larry L
LL
Baron
Michael
M
D000293:Adolescent; D000328:Adult; D000588:Amines / Q000009:adverse effects / Q000627:therapeutic use*; D019969:Amphetamine-Related Disorders / Q000188:drug therapy*; D000927:Anticonvulsants / Q000627:therapeutic use*; D016739:Behavior, Addictive / Q000188:drug therapy*; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods; D005260:Female; D005442:Flumazenil / Q000009:adverse effects / Q000627:therapeutic use*; D018757:GABA Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000627:therapeutic use*
D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D018757:GABA Modulators; D005442:Flumazenil; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin